Protalix BioTherapeutics, Inc. (AMEX:PLX) was founded in 1993 and is headquartered in Karmiel, Israel. It employs 190 full-time people. It is a biopharmaceutical company that focuses on recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and around the world Development and commercialization.
Protalix BioTherapeutics, Inc. (PLX):
Protalix was founded by Dr. Yoseph Shaaltiel and started as a greenhouse company in 1993 in Kiryat Shmona, a town in northern Israel. The first production plant was built in Carmiel, West Galilee in May 2004, and was later expanded and upgraded at the end of 2009 to prepare for the commercial production of Elelyso® and the production of the clinical trial product line.
Protalix BioTherapeutics company maintains the world’s highest product quality and quality assurance standards. Protalix BioTherapeutics’ cGMP production facilities have successfully passed inspections and audits by multiple regulatory agencies, including the US FDA, EMA, Australian TGA, Brazil ANVISA and the Israeli Ministry of Health.
Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® plant cell protein expression system. Protalix’s product line includes proprietary, recombinant therapeutic protein versions with potential clinical advantages, targeting the mature pharmaceutical market.
Products & candidate products include:
1. Elelyso, plant cells express recombinant glucocerebrosidase for the treatment of Gaucher disease.
2. PRX-102, a therapeutic protein candidate, is in phase III clinical trials for the treatment of Fabry.
3. PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I, is in a phase IIa clinical trial for the treatment of cystic fibrosis.
4. OPRX-106, an oral anti-TNF product candidate, is in phase IIa clinical trials for the treatment of ulcerative colitis.